alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 31**

 

**EXHIBIT 31 — SECTION 302 CERTIFICATIONS**

 

I, Theodore L. Arena, and I, Thomas J. Mulroney, each separately certify that: 

 

1. I have reviewed this quarterly report on Form 10-Q of Provena Foods Inc. (the “Company”); 

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary tomake the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all materialrespects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; 

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e) and l5d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the Company and have: 

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the Company, including any subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

 

b) Designed such internal control over financial reporting, or caused suchinternal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance withgenerally accepted accounting principles; 

 

c) Evaluated theeffectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and 

 

d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recentfiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and 

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theCompany’s auditors and the audit committee of the Company’s board of directors: 

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record,process, summarize and report financial information; and 

 

b)Any fraud. whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. 

 

Date: April 29, 2004
# C_2019082EN.01002701.xml

| 4.3.2019 | EN | Official Journal of the European Union | C 82/27 |
| --- | --- | --- | --- |

4.3.2019

EN

Official Journal of the European Union

C 82/27

---

Judgment of the General Court of 12 December 2018 — Krka v Commission

(Case T-684/14) (1)

((Competition - Agreements, decisions and concerted practices - Market for perindopril, a medicinal product intended for the treatment of cardiovascular diseases, in its originator and generic versions - Decision finding an infringement of Article 101 TFEU - Patent dispute settlement agreement - Licensing agreement - Technology acquisition agreement - Restriction of competition by object - Restriction of competition by effect - Balance between competition law and patent law))

(2019/C 82/30)

Language of the case: English

Parties

Applicant: Krka Tovarna Zdravil d.d. (Novo Mesto, Slovenia) (represented by T. Ilešič and M. Kocmut, lawyers)

Defendant: European Commission (represented by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, assisted by D. Bailey, Barrister)

Re:

Application under Article 263 TFEU for partial annulment of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU [Case AT.39612 — Perindopril (Servier)] in so far as it concerns the applicant.

Operative part of the judgment

The Court:

| 1. | Annuls Article 4 of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU (Case AT.39612 — Perindopril (Servier)) in so far as it finds that Krka Tovarna Zdravil d.d. participated in the agreements referred to in that article; |
| --- | --- |

1.

Annuls Article 4 of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU (Case AT.39612 — Perindopril (Servier)) in so far as it finds that Krka Tovarna Zdravil d.d. participated in the agreements referred to in that article;

| 2. | Annuls Article 7(4)(a) of Decision C(2014) 4955 final; |
| --- | --- |

2.

Annuls Article 7(4)(a) of Decision C(2014) 4955 final;

| 3. | Annuls Articles 8 and 9 of Decision C(2014) 4955 final, in so far as they concern Krka Tovarna Zdravil; |
| --- | --- |

3.

Annuls Articles 8 and 9 of Decision C(2014) 4955 final, in so far as they concern Krka Tovarna Zdravil;

| 4. | Orders the Commission to pay the costs. |
| --- | --- |

4.

Orders the Commission to pay the costs.

---

(1)  OJ C 431, 1.12.2014.

---
**Exhibit
      15.2**











To
      the
      Board of Directors and Partners of


Icahn
      Enterprises L.P.





We
      are
      aware of the inclusion in Icahn Enterprises L.P.’s Form 10-Q for the quarter
      ended September 30, 2008 and the incorporation by reference in Icahn Enterprises
      L.P.’s Registration Statements (Forms S-3 Nos. 333-126069 and 333-143930 and
      Form S-4 No. 333-143929) of our review report dated October 22, 2008 relating
      to
      the unaudited consolidated interim financial statements of Federal-Mogul
      Corporation as of September 30, 2008 and for the three-month and nine-month
      periods ended September 30, 2008, which is included in Federal-Mogul
      Corporation’s Form 10-Q for the quarter ended September 30, 2008.











/s/
      Ernst
& Young LLP


Detroit,
      Michigan


November
      5, 2008
<PAGE>
                                                                    EXHIBIT 99.1

                                  CERTIFICATION

        Pursuant to Section 906 of the Public Company Accounting Reform and
Investor Protection Act of 2002 (18 U.S.C. Section 1350, as adopted), Nathan
Zommer, the Chief Executive Officer of IXYS Corporation (the "Company"), and
Arnold P. Agbayani, the Chief Financial Officer of the Company, each hereby
certifies that, to the best of his knowledge:

1. The Company's amendment on Form 10-K/A, amending the Annual Report on Form
10-K for the period ended March 31, 2002, to which this Certification is
attached as Exhibit 99.1 (the "Periodic Report"), fully complies with the
requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of
1934, as amended; and

2. The information contained in the Periodic Report fairly presents, in all
material respects, the financial condition of the Company at the end of the
period covered by the Periodic Report and results of operations of the Company
for the period covered by the Periodic Report.

Dated: October 21, 2002

                               By:  /s/ Nathan Zommer
                                    --------------------------------------
                                    Nathan Zommer, Chief Executive Officer


                               By:  /s/ Arnold P. Agbayani
                                    -------------------------------------------
                                    Arnold P. Agbayani, Chief Financial Officer
SPENCER CLEMONS,

Petitioner,

v.

STATE OF FLORIDA,

Respondent.

___________________________/

IN THE DISTRICT COURT OF APPEAL

FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO 

FILE MOTION FOR REHEARING AND 

DISPOSITION THEREOF IF FILED

CASE NO. 1D17-0178

Opinion filed February 6, 2017.

Amended Petition for Writ of Prohibition -- Original Jurisdiction.

Anabelle Dias of Anabelle Dias P.A., Tallahassee, for Petitioner.

Pamela Jo Bondi, Attorney General, Tallahassee, for Respondent.

PER CURIAM.

The amended petition for writ of prohibition is denied on the merits.

LEWIS, BILBREY, and WINOKUR, JJ., CONCUR.
EX-4.1



 Exhibit 4.1 

 

	
	 






  
 THIS CERTIFICATE IS TRANSFERABLE IN SOUTH SAINT PAUL. MN. 
 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 
 SEE REVERSE SIDE FOR CERTAIN DEFINITIONS 
 CUSIP
40412C 10 1 
 THIS CERTIFIES THAT 
 is the owner of 
 FULLY PAID AND NON-ASSESSABLE
COMMON SHARES, $0.01 PAR VALUE, OF 
 HCA HEALTHCARE, INC. 

transferable on the books of the Corporation by the holder hereof in person or by Attorney upon surrender of this
certificate properly endorsed. This certificate is not valid until countersigned and registered by the Transfer Agent and Registrar. 
 IN WITNESS WHEREOF, the said Corporation has caused this certificate to be signed by facsimile signatures of its duly authorized officers. 

Dated: 
 CHAIRMAN AND CHIEF EXECUTIVE OFFICER 
 VICE
PRESIDENT-LEGAL AND CORPORATE SECRETARY 
 AMERICAN FINANCIAL PRINTING INCORPORATED- MINNEAPOLIS 

COUNTERSIGNED AND REGISTERED: WELLS FARGO BANK, N.A. 

BY 
 TRANSFER AGENT AND REGISTRAR 
 AUTHORIZED SIGNATURE








 



 
  
 THE BOARD
OF THIS CORPORATION HAS THE AUTHORITY TO CREATE AND DETERMINE THE RELATIVE RIGHTS AND PREFERENCES OF CLASSES OR SERIES OF SHARES OF CAPITAL STOCK OTHER THAN COMMON STOCK THIS CORPORATION WILL FURNISH TO ANY SHAREHOLDER UPON WRITTEN REQUEST SENT TO
ITS PRINCIPAL EXECUTIVE OFFICES, AND WITHOUT CHARGE, A FULL STATEMENT OF THE BOARD’S AUTHORITY TO CREATE AND DETERMINE THE RELATIVE RIGHTS AND PREFERENCES OF CLASSES OR SERIES OF SHARES OF CAPITAL STOCK AS WELL AS THE DESIGNATIONS, PREFERENCES,
LIMITATIONS AND RELATIVE RIGHTS OF THE SHARES OF EACH CLASS OR SERIES THEN OUTSTANDING OR AUTHORIZED TO BE ISSUED. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were
written out in full according to applicable laws or regulations: UTMA- Custodian TEN COM - as tenants In common (Cust) (Minor) TEN ENT - as tenants by entireties 
 under Uniform Transfers to Minors JT TEN - as joint tenants with right of survivorship and not as tenants in common Act (State) 

Additional abbreviations may also be used though not in above list. For value received hereby sell, assign, and transfer
into PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING ZIP CODE OF ASSIGNEE) Shares of the capital stock represented by the within Certificate, and do hereby irrevocably
constitute and appoint Attorney to transfer the said stock on the books of the within-named Corporation with power of substitution in the premises. Dated NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE
OF THE CERTIFICATE IN EVERY PARTICULAR WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER. SIGNATURE GUARANTEED ALL GUARANTEES MUST BE MADE BY A FINANCIAL INSTITUTION (SUCH AS A BANK OR BROKER) WHICH IS A PARTICIPANT IN THE SECURITIES TRANSFER
AGENTS MEDALLION PROGRAM (“STAMP”), THE NEW YORK STOCK EXCHANGES MEDALLION PROGRAM (“SEMP”) AND MUST NOT BE DATED. GUARANTEES BY A PUBLIC ARE NOT ACCEPTABLE.
§ 522.2450 Tigilanol. ( a ) *Specifications.* Each milliliter (mL) of solution contains 1 milligram tigilanol tiglate.
( b ) *Sponsor.* See No. 086132 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer as an intratumoral injection at a dose of 0.5 mL per cubic centimeter of tumor volume.
( 2 ) *Indications for use.* For the treatment of non-metastatic cutaneous mast cell tumors and non-metastatic subcutaneous mast cell tumors located at or distal to the elbow or the hock in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[86 FR 17064, Apr. 1, 2021]
§ 524.1484g Neomycin, thiabendazole, and dexamethasone solution. ( a ) *Specifications.* Each milliliter of solution contains 40 milligrams (mg) thiabendazole, 3.2 mg neomycin (from neomycin sulfate), and 1 mg dexamethasone.
( b ) *Sponsors.* See Nos. 000010 and 017033 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* In treating dermatoses affecting areas other than the ear, the surface of the lesions should be well moistened (2 to 4 drops per square inch) twice daily. In treating otitis externa, instill 5 to 15 drops in the ear twice daily. Treat for up to 7 days.
( 2 ) *Indications for use.* As an aid in the treatment of bacterial, mycotic, and inflammatory dermatoses and otitis externa.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 63271, Nov. 28, 1997; 79 FR 10971, Feb. 27, 2014; 80 FR 61297, Oct. 13, 2015; 84 FR 39184, Aug. 9, 2019; 88 FR 16549, Mar. 20, 2023]
#### Kolosky v. Philadelphia Workingmen’s Saving, Loan and Building Association

*Hymen Schwartz,*for plaintiff.

*Harry Shapiro,*for defendant.

June 28,1951.

Oliver, P. J.,

— This matter is before us on plaintiff’s bill in equity for the appointment of a receiver for defendant building and loan association.

In 1938 the stockholders of defendant association resolved upon a voluntary liquidation. Since that time three trustees have been conducting the liquidation. *576Plaintiff’s bill asserts that the trustees have disagreed, and that their disagreement jeopardizes completion of the liquidation. Defendant’s answer denies that a receiver is required. Defendant further avers that the best interest of the association will be served if this court will rule that the trustees may act by a majority vote rather than by a unanimous vote.

Section 1110(B) of the Building and Loan Code of May 5, 1933, P. L. 457, 15 PS §1074-1110, grants to the State Department of Banking the power to take possession of a building, and loan association which is in the process of voluntary dissolution. It is admitted that the power granted to the Banking Department is a discretionary one. In the instant case, the Banking Department was requested to take over defendant association but, after a hearing on the merits, declined to do so. For this reason, plaintiff contends that this court should now appoint a private receiver.

Section 606 of the Department of Banking Code of May 15,1933, P. L. 565, 71 PS §733-606, provides that, in cases of this type, “no court shall appoint anyone but the Secretary (of Banking) as receiver for an institution”. It is apparent, therefore, that we have no jurisdiction to appoint a private receiver as plaintiff requests. We are of the opinion that, if plaintiff seeks to review the action of the Secretary of Banking, she should file a writ of mandamus in the Dauphin County court.

Since we have no jurisdiction to grant the relief sought by plaintiff, the question of whether the trustees should act by a majority or by a unanimous vote cannot be adjudicated at this time. If defendant believes that this question must be settled, it should bring it affirmatively before the court in an appropriate proceeding. Bill dismissed. Plaintiff to pay costs.
§ 522.224 Bupivacaine. ( a ) *Specifications.* Each milliliter (mL) of liposomal suspension contains 13.3 milligrams (mg) bupivacaine.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Administer 5.3 mg/kg (0.4 mL/kg) by infiltration injection into the tissue layers at the time of incisional closure.
( ii ) *Indications for use.* For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery.
( 2 ) *Cats* — ( i ) *Amount.* Administer 5.3 mg/kg per forelimb (0.4 mL/kg per forelimb), for a total dose of 10.6 mg/kg/cat, as a 4-point nerve block prior to onychectomy.
( ii ) *Indications for use.* For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy.
[81 FR 67151, Sept. 30, 2016, as amended at 84 FR 8973, Mar. 13, 2019; 85 FR 4208, Jan. 24, 2020]
§ 7.46 Firm-initiated recall. ( a ) A firm may decide of its own volition and under any circumstances to remove or correct a distributed product. A firm that does so because it believes the product to be violative is requested to notify immediately the appropriate Food and Drug Administration district office listed in § 5.115 of this chapter. Such removal or correction will be considered a recall only if the Food and Drug Administration regards the product as involving a violation that is subject to legal action, e.g., seizure. In such cases, the firm will be asked to provide the Food and Drug Administration the following information: ( 1 ) Identity of the product involved.
( 2 ) Reason for the removal or correction and the date and circumstances under which the product deficiency or possible deficiency was discovered.
( 3 ) Evaluation of the risk associated with the deficiency or possible deficiency.
( 4 ) Total amount of such products produced and/or the timespan of the production.
( 5 ) Total amount of such products estimated to be in distribution channels.
( 6 ) Distribution information, including the number of direct accounts and, where necessary, the identity of the direct accounts.
( 7 ) A copy of the firm's recall communication if any has issued, or a proposed communication if none has issued.
( 8 ) Proposed strategy for conducting the recall.
( 9 ) Name and telephone number of the firm official who should be contacted concerning the recall.
( b ) The Food and Drug Administration will review the information submitted, advise the firm of the assigned recall classification, recommend any appropriate changes in the firm's strategy for the recall, and advise the firm that its recall will be placed in the weekly FDA Enforcement Report. Pending this review, the firm need not delay initiation of its product removal or correction.
( c ) A firm may decide to recall a product when informed by the Food and Drug Administration that the agency has determined that the product in question violates the law, but the agency has not specifically requested a recall. The firm's action also is considered a firm-initiated recall and is subject to paragraphs (a) and (b) of this section.
( d ) A firm that initiates a removal or correction of its product which the firm believes is a market withdrawal should consult with the appropriate Food and Drug Administration district office when the reason for the removal or correction is not obvious or clearly understood but where it is apparent, e.g., because of complaints or adverse reactions regarding the product, that the product is deficient in some respect. In such cases, the Food and Drug Administration will assist the firm in determining the exact nature of the problem.
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2250 Iron oxides. ( a ) *Identity.* The color additives iron oxides consist of any one or any combination of synthetically prepared iron oxides, including the hydrated forms. It is free from admixture with other substances.
( b ) *Specifications.* Iron oxides shall conform to the following specifications, all on an “as is” basis: Arsenic (as As), not more than 3 parts per million. Lead (as Pb), not more than 10 parts per million. Mercury (as Hg), not more than 3 parts per million.
( c ) *Uses and restrictions.* Iron oxides are safe for use in coloring cosmetics generally, including cosmetics applied to the area of the eye, in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The color additive and any mixture prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to any information required by law, labeling in accordance with § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from certification pursuant to section 721(c) of the act.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-23-2000
<PERIOD-START>                             DEC-26-1999
<PERIOD-END>                               MAR-25-2000
<CASH>                                           2,853
<SECURITIES>                                         0
<RECEIVABLES>                                   63,323
<ALLOWANCES>                                    10,266
<INVENTORY>                                     25,728
<CURRENT-ASSETS>                                94,331
<PP&E>                                         104,395
<DEPRECIATION>                                  34,723
<TOTAL-ASSETS>                                 342,836
<CURRENT-LIABILITIES>                           64,830
<BONDS>                                        225,120
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            81
<OTHER-SE>                                      55,423
<TOTAL-LIABILITY-AND-EQUITY>                   342,836
<SALES>                                         68,089
<TOTAL-REVENUES>                                68,089
<CGS>                                           48,797
<TOTAL-COSTS>                                   48,797
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               5,137
<INCOME-PRETAX>                                (2,098)
<INCOME-TAX>                                     (881)
<INCOME-CONTINUING>                            (1,217)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,217)
<EPS-BASIC>                                     (0.17)
<EPS-DILUTED>                                   (0.17)



</TABLE>